Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Farewell, comet 3I/ATLAS! Interstellar visitor heads for the outer solar system after its closest approach to Earth - 2Interstellar comet 3I/ATLAS to pass closest to Earth on Friday
- 3'No middle ground' for tackling antisemitism after Bondi Beach mass shooting, deputy FM Haskel says
- 4Kids who get 2-month vaccines on time 7 times more likely to receive MMR shot: Study
- 5A Manual for Nations to Head out To
- Step in Style: A Survey of \Solace and Execution on the Track\ Running Shoes
- Top 15 Supportable Design Brands Coming out on top
- Dwayne ‘the Rock’ Johnson opens up about being the 'new guy' again — and why this moment feels like a new life
- Study finds humans were making fire 400,000 years ago, far earlier than once thought
- Palestinians protest against Israel's new death penalty law
- Warning for snow and ice extended
- Excelling at Discussion: Genuine Examples of overcoming adversity
- Flu cases are rising with a strain that makes older people sicker
- Get To Be familiar with The Historical backdrop Of Western Medication
